• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Monica M. Bertagnolli, MD


  • Shiovitz S, Bertagnolli MM, Renfro LA, Nam E, Foster NR, Dzieciatkowski S, Luo Y, Lao VV, Monnat RJ, Emond MJ, Maizels N, Niedzwiecki D, Goldberg RM, Saltz LB, Venook A, Warren RS, Grady WM, .CpG Island Methylator Phenotype is Associated With Response to Adjuvant Irinotecan-Based Therapy for Stage 3 Colon Cancer.Gastroenterology. 2014 May 21.
  • Fiore M, Coppola S, Cannell AJ, Colombo C, Bertagnolli MM, George S, Le Cesne A, Gladdy RA, Casali PG, Swallow CJ, Gronchi A, Bonvalot S, Raut CP.Desmoid-Type Fibromatosis and Pregnancy: A Multi-institutional Analysis of Recurrence and Obstetric Risk.Ann Surg. 2014 May;259(5):973-8.
  • Serrano C, Wang Y, Mariño-Enríquez A, Lee JC, Ravegnini G, Morgan JA, Bertagnolli MM, Beadling C, Demetri GD, Corless CL, Heinrich MC, Fletcher JA.KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation.J Clin Oncol. 2014 Mar 31.
  • Hasson RM, Briggs A, Rizvi H, Carothers AM, Davids JS, Bertagnolli MM, Cho NL.Lack of anti-tumor activity with the β-catenin expression inhibitor EZN-3892 in the C57BL/6J Min/+ model of intestinal carcinogenesis.Biochem Biophys Res Commun. 2014 Feb 14;444(3):283-9.
  • Keung EZ, Hornick JL, Bertagnolli MM, Baldini EH, Raut CP.Predictors of outcomes in patients with primary retroperitoneal dedifferentiated liposarcoma undergoing surgery.J Am Coll Surg. 2014 Feb;218(2):206-17.
  • Hasson RM, Briggs A, Carothers AM, Davids JS, Wang J, Javid SH, Cho NL, Bertagnolli MM.Estrogen receptor α or β loss in the colon of Min/+ mice promotes crypt expansion and impairs TGFβ and HNF3β signaling.Carcinogenesis. 2014 Jan;35(1):96-102.
  • Nixon AB, Pang H, Starr MD, Friedman PN, Bertagnolli MM, Kindler HL, Goldberg RM, Venook AP, Hurwitz HI, .Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance).Clin Cancer Res. 2013 Dec 15;19(24):6957-66.
  • Ogino S, Liao X, Imamura Y, Yamauchi M, McCleary NJ, Ng K, Niedzwiecki D, Saltz LB, Mayer RJ, Whittom R, Hantel A, Benson AB, Mowat RB, Spiegelman D, Goldberg RM, Bertagnolli MM, Meyerhardt JA, Fuchs CS, .Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.Journal of the National Cancer Institute. 2013 Dec 4;105(23):1789-98.
  • Wang J, Carvajal-Carmona LG, Chu JH, Zauber AG, , Kubo M, Matsuda K, Dunlop M, Houlston RS, Sieber O, Lipton L, Gibbs P, Martin NG, Montgomery GW, Young J, Baird PN, Ratain MJ, Nakamura Y, Weiss ST, Tomlinson I, Bertagnolli MM.Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study.Clin Cancer Res. 2013 Dec 1;19(23):6430-7.
  • Warren RS, Atreya CE, Niedzwiecki D, Weinberg VK, Donner DB, Mayer RJ, Goldberg RM, Compton CC, Zuraek MB, Ye C, Saltz LB, Bertagnolli MM.Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803.Clin Cancer Res. 2013 Oct 15;19(20):5777-87.
  • Sinicrope FA, Mahoney MR, Smyrk TC, Thibodeau SN, Warren RS, Bertagnolli MM, Nelson GD, Goldberg RM, Sargent DJ, Alberts SR.Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.J Clin Oncol. 2013 Oct 10;31(29):3664-72.
  • Baldini EH, Lapidus MR, Wang Q, Manola J, Orgill DP, Pomahac B, Marcus KJ, Bertagnolli MM, Devlin PM, George S, Abraham J, Ferrone ML, Ready JE, Raut CP.Predictors for major wound complications following preoperative radiotherapy and surgery for soft-tissue sarcoma of the extremities and trunk: importance of tumor proximity to skin surface.Ann Surg Oncol. 2013 May;20(5):1494-9.
  • Venook AP, Niedzwiecki D, Lopatin M, Ye X, Lee M, Friedman PN, Frankel W, Clark-Langone K, Millward C, Shak S, Goldberg RM, Mahmoud NN, Warren RS, Schilsky RL, Bertagnolli MM.Biologic Determinants of Tumor Recurrence in Stage II Colon Cancer: Validation Study of the 12-Gene Recurrence Score in Cancer and Leukemia Group B (CALGB) 9581.J Clin Oncol. 2013 Mar 25.
  • Carvajal-Carmona LG, Zauber AG, Jones AM, Howarth K, Wang J, Cheng T, , , , , , Riddell R, Lanas A, Morton D, Bertagnolli MM, Tomlinson I.Much of the Population Genetic Risk of Colorectal Cancer Is Likely to Be Mediated Through Susceptibility to Adenomas.Gastroenterology. 2012 Sep 19.
  • Cho NL, Carothers AM, Rizvi H, Hasson RM, Redston M, Bertagnolli MM.Immunohistochemical and Molecular Analysis of Tyrosine Kinase Activity in Desmoid Tumors.J Surg Res. 2010 Nov 26.
  • Goldberg RM, Bertagnolli MM.VICTOR spoiled?.J Clin Oncol. 2010 Oct 20;28(30):4546-8.
  • Carothers AM, Davids JS, Damas BC, Bertagnolli MM.Persistent cyclooxygenase-2 inhibition downregulates NF-{kappa}B, resulting in chronic intestinal inflammation in the min/+ mouse model of colon tumorigenesis.Cancer Res. 2010 Jun 1;70(11):4433-42.
  • Peppercorn J, Shapira I, Collyar D, Deshields T, Lin N, Krop I, Grunwald H, Friedman P, Partridge AH, Schilsky RL, Bertagnolli MM.Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology.J Clin Oncol. 2010 May 20;28(15):2635-40.
  • Bertagnolli MM, Hsu M, Hawk ET, Eagle CJ, Zauber AG, .Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial.Cancer Prev Res (Phila Pa). 2010 May;3(5):588-96.
  • Davids JS, Carothers AM, Damas BC, Bertagnolli MM.Chronic cyclooxygenase-2 inhibition promotes myofibroblast-associated intestinal fibrosis.Cancer Prev Res (Phila Pa). 2010 Mar;3(3):348-58.
  • Raut CP, Wang Q, Manola J, Morgan JA, George S, Wagner AJ, Butrynski JE, Fletcher CD, Demetri GD, Bertagnolli MM.Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate.Ann Surg Oncol. 2010 Feb;17(2):407-15.
  • Markowitz SD, Bertagnolli MM.Molecular origins of cancer: Molecular basis of colorectal cancer.N Engl J Med. 2009 Dec 17;361(25):2449-60. Review.
  • Bertagnolli MM.The forest and the trees: pathways and proteins as colorectal cancer biomarkers.J Clin Oncol. 2009 Dec 10;27(35):5866-7.
  • Ogino S, Meyerhardt JA, Irahara N, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Schaefer P, Whittom R, Hantel A, Benson AB, Goldberg RM, Bertagnolli MM, Fuchs CS, , , , .KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.Clin Cancer Res. 2009 Dec 1;15(23):7322-9.
  • Raut CP, Nucci MR, Wang Q, Manola J, Bertagnolli MM, Demetri GD, Morgan JA, Muto MG, Fletcher CD, George S.Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma.Eur J Cancer. 2009 Nov;45(16):2818-24.
  • Mery CM, George S, Bertagnolli MM, Raut CP.Secondary sarcomas after radiotherapy for breast cancer: sustained risk and poor survival.Cancer. 2009 Sep 15;115(18):4055-63.
  • Yan M,Myung SJ,Fink SP,Lawrence E,Lutterbaugh J,Yang P,Zhou X,Liu D,Rerko RM,Willis J,Dawson D,Tai HH,Barnholtz-Sloan JS,Newman RA,Bertagnolli MM,Markowitz SD.15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors.Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9409-13.
  • Chan AT,Zauber AG,Hsu M,Breazna A,Hunter DJ,Rosenstein RB,Eagle CJ,Hawk ET,Bertagnolli MM.Cytochrome P450 2C9 Variants Influence Response to Celecoxib for Prevention of Colorectal Adenoma.Gastroenterology. 2009 Jun;136(7):2127-2136.e1.
  • Bertagnolli MM,Eagle CJ,Zauber AG,Redston M,Breazna A,Kim K,Tang J,Rosenstein RB,Umar A,Bagheri D,Collins NT,Burn J,Chung DC,Dewar T,Foley TR,Hoffman N,Macrae F,Pruitt RE,Saltzman JR,Salzberg B,Sylwestrowicz T,Hawk ET.Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial.Cancer Prev Res (Phila Pa). 2009 Apr;2(4):310-21.
  • Raut CP,Bertagnolli MM.Controversies in the surgical management of GIST in the era of imatinib.Oncology (Huntingt). 2009 Jan;23(1):69, 74-6.
  • Bertagnolli MM,Warren RS,Niedzwiecki D,Mueller E,Compton CC,Redston M,Hall M,Hahn HP,Jewell SD,Mayer RJ,Goldberg RM,Saltz LB,Loda M.p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803.Clin Cancer Res. 2009 Mar 15;15(6):2116-22.
  • Bertagnolli MM,Niedzwiecki D,Compton CC,Hahn HP,Hall M,Damas B,Jewell SD,Mayer RJ,Goldberg RM,Saltz LB,Warren RS,Redston M.Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.J Clin Oncol. 2009 Apr 10;27(11):1814-21.
  • Bertagnolli MM,Zauber AG,Solomon S.Prostaglandin inhibition and cardiovascular risk: maybe timing really is everything.Cancer Prev Res (Phila Pa). 2009 Mar;2(3):195-6.
  • Cho NL,Redston M,Zauber AG,Carothers AM,Hornick J,Wilton A,Sontag S,Nishioka N,Giardiello FM,Saltzman JR,Gostout C,Eagle CJ,Hawk ET,Bertagnolli MM.Aberrant crypt foci in the adenoma prevention with celecoxib trial.Cancer Prev Res (Phila Pa). 2008 Jun;1(1):21-31.
  • Wirth LJ,Krane JF,Li Y,Othus M,Moran AE,Dorfman DM,Norris CM Jr,Goguen L,Posner MR,Haddad RI,Bertagnolli MM.A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions.Cancer Prev Res (Phila Pa). 2008 Oct;1(5):339-48.
  • Lin CI,Whang EE,Abramson MA,Donner DB,Bertagnolli MM,Moore FD Jr,Ruan DT.Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid cancer cells.Biochem Biophys Res Commun. 2009 Feb 6;379(2):626-31.
  • Bertagnolli MM.Doing our best: surgery for rectal cancer.Gut. 2008 Dec;57(12):1643-5.
  • Heinrich MC,Owzar K,Corless CL,Hollis D,Borden EC,Fletcher CD,Ryan CW,von Mehren M,Blanke CD,Rankin C,Benjamin RS,Bramwell VH,Demetri GD,Bertagnolli MM,Fletcher JA.Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.J Clin Oncol. 2008 Nov 20;26(33):5360-7.
  • Bertagnolli MM,Morgan JA,Fletcher CD,Raut CP,Dileo P,Gill RR,Demetri GD,George S.Multimodality treatment of mesenteric desmoid tumours.Eur J Cancer. 2008 Nov;44(16):2404-10.
  • Chan JA,Meyerhardt JA,Niedzwiecki D,Hollis D,Saltz LB,Mayer RJ,Thomas J,Schaefer P,Whittom R,Hantel A,Goldberg RM,Warren RS,Bertagnolli M,Fuchs CS.Association of family history with cancer recurrence and survival among patients with stage III colon cancer.JAMA. 2008 Jun 4;299(21):2515-23.
  • Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, Arber N, Levin B, Meinert CL, Martin B, Pater JL, Goss PE, Lance P, Obara S, Chew EY, Kim J, Arndt G, Hawk E.Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.Circulation. 2008 Apr 22;117(16):2104-13.
  • Ito H, Hornick JL, Bertagnolli MM, George S, Morgan JA, Baldini EH, Wagner AJ, Demetri GD, Raut CP.Leiomyosarcoma of the inferior vena cava: survival after aggressive management.Ann Surg Oncol. 2007 Dec;14(12):3534-41.
  • Bertagnolli MM.Chemoprevention of colorectal cancer with cyclooxygenase-2 inhibitors: two steps forward, one step back.Lancet Oncol. 2007 May;8(5):439-43. Review.
  • Cho NL, Javid SH, Carothers AM, Redston M, Bertagnolli MM.Estrogen receptors alpha and beta are inhibitory modifiers of Apc-dependent tumorigenesis in the proximal colon of Min/+ mice.Cancer Res. 2007 Mar 1;67(5):2366-72.
  • Bertagnolli MM.Cox-2 and cancer chemoprevention: picking up the pieces.Recent Results Cancer Res. 2007;174:73-8. Review.
  • Goel A, Nagasaka T, Arnold CN, Inoue T, Hamilton C, Niedzwiecki D, Compton C, Mayer RJ, Goldberg R, Bertagnolli MM, Boland CR.The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer.Gastroenterology. 2007 Jan;132(1):127-38.
  • Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Levin B, Eagle C, Hawk E, Lechuga M, Zauber AG, Bertagnolli MM, Arber N, Wittes J,.Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas.Circulation. 2006 Sep 5;114(10):1028-35.
  • Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET.Celecoxib for the prevention of sporadic colorectal adenomas.N Engl J Med. 2006 Aug 31;355(9):873-84.
  • Carothers AM, Moran AE, Cho NL, Redston M, Bertagnolli MM.Changes in antitumor response in C57BL/6J-Min/+ mice during long-term administration of a selective cyclooxygenase-2 inhibitor.Cancer Res. 2006 Jun 15;66(12):6432-8.
  • Goldberg RM, Niedzwiecki D, Bertagnolli M, Blackstock AW, Tepper JE, Mayer RJ.Cancer and leukemia group B gastrointestinal cancer committee.Clin Cancer Res. 2006 Jun 1;12(11 Pt 2):3589s-95s. Review.
  • Raut CP, Posner M, Desai J, Morgan JA, George S, Zahrieh D, Fletcher CD, Demetri GD, Bertagnolli MM.Surgical Management of Advanced Gastrointestinal Stromal Tumors After Treatment With Targeted Systemic Therapy Using Kinase Inhibitors.J Clin Oncol. 2006 May 20;24(15):2325-2331.
  • Redston M, Compton CC, Miedema BW, Niedzwiecki D, Dowell JM, Jewell SD, Fleshman JM, Bem J, Mayer RJ, Bertagnolli MM,.Analysis of micrometastatic disease in sentinel lymph nodes from resectable colon cancer: results of Cancer and Leukemia Group B Trial 80001.J Clin Oncol. 2006 Feb 20;24(6):878-83.
  • Carothers AM, Javid SH, Moran AE, Hunt DH, Redston M, Bertagnolli MM.Deficient E-cadherin adhesion in C57BL/6J-Min/+ mice is associated with increased tyrosine kinase activity and RhoA-dependent actomyosin contractility.Exp Cell Res. 2006 Feb 15;312(4):387-400.
  • George S, Hornick JL, Bertagnolli MM, Fletcher CD, Demetri GD.Current management of metastatic gastrointestinal stromal tumor: a case report.Clin Adv Hematol Oncol. 2003 Jan;1(1):63-4; discussion 65.
  • Bertagnolli MM.Radioimmunotherapy for colorectal cancer.Clin Cancer Res. 2005 Jul 1;11(13):4637-8.
  • Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M,.Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.N Engl J Med. 2005 Mar 17;352(11):1071-80.
  • Moran AE, Carothers AM, Weyant MJ, Redston M, Bertagnolli MM.Carnosol inhibits beta-catenin tyrosine phosphorylation and prevents adenoma formation in the C57BL/6J/Min/+ (Min/+) mouse.Cancer Res. 2005 Feb 1;65(3):1097-104.
  • Bertagnolli MM.Surgical prevention of cancer.J Clin Oncol. 2005 Jan 10;23(2):324-32.
  • Javid SH, Moran AE, Carothers AM, Redston M, Bertagnolli MM.Modulation of tumor formation and intestinal cell migration by estrogens in the Apc(Min/+) mouse model of colorectal cancer.Carcinogenesis. 2005 Mar;26(3):587-95.
  • Moran AE, Hunt DH, Javid SH, Redston M, Carothers AM, Bertagnolli MM.Apc deficiency is associated with increased Egfr activity in the intestinal enterocytes and adenomas of C57BL/6J-Min/+ mice.J Biol Chem. 2004 Oct 8;279(41):43261-72.
  • Bertagnolli M, Miedema B, Redston M, Dowell J, Niedzwiecki D, Fleshman J, Bem J, Mayer R, Zinner M, Compton C.Sentinel node staging of resectable colon cancer: results of a multicenter study.Ann Surg. 2004 Oct;240(4):624-8; discussion 628-30.
  • Goel A, Arnold CN, Tassone P, Chang DK, Niedzwiecki D, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM, Boland CR.Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers.Int J Cancer. 2004 Dec 10;112(5):754-9.
  • Kulke MH, Odze RD, Mueller JD, Wang H, Redston M, Bertagnolli MM.Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer.J Thorac Cardiovasc Surg. 2004 Jun;127(6):1579-86.
  • Goel A, Arnold CN, Niedzwiecki D, Carethers JM, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM, Boland CR.Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers.Cancer Res. 2004 May 1;64(9):3014-21.
  • Arnold CN, Goel A, Compton C, Marcus V, Niedzwiecki D, Dowell JM, Wasserman L, Inoue T, Mayer RJ, Bertagnolli MM, Boland CR.Evaluation of microsatellite instability, hMLH1 expression and hMLH1 promoter hypermethylation in defining the MSI phenotype of colorectal cancer.Cancer Biol Ther. 2004 Jan;3(1):73-8.
  • Bertagnolli MM.The potential of non-steroidal anti-inflammatory drugs (NSAIDs) for colorectal cancer prevention.J Surg Oncol. 2003 Nov;84(3):113-9.
  • Bertagnolli MM.Colorectal cancer prevention studies: the importance of defining disease risk.Ann Surg Oncol. 2003 Oct;10(8):829-30.
  • Goel A, Arnold CN, Niedzwiecki D, Chang DK, Ricciardiello L, Carethers JM, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM, Boland CR.Characterization of sporadic colon cancer by patterns of genomic instability.Cancer Res. 2003 Apr 1;63(7):1608-14.
  • Hughes SA, Carothers AM, Hunt DH, Moran AE, Mueller JD, Bertagnolli MM.Adenomatous polyposis coli truncation alters cytoskeletal structure and microtubule stability in early intestinal tumorigenesis.J Gastrointest Surg. 2002 Nov-Dec;6(6):868-74; discussion 875.
  • Carothers AM, Hughes SA, Ortega D, Bertagnolli MM.2-Methoxyestradiol induces p53-associated apoptosis of colorectal cancer cells.Cancer Lett. 2002 Dec 10;187(1-2):77-86.
  • O'Shaughnessy JA, Kelloff GJ, Gordon GB, Dannenberg AJ, Hong WK, Fabian CJ, Sigman CC, Bertagnolli MM, Stratton SP, Lam S, Nelson WG, Meyskens FL, Alberts DS, Follen M, Rustgi AK, Papadimitrakopoulou V, Scardino PT, Gazdar AF, Wattenberg LW, Sporn MB, Sakr WA, Lippman SM, Von Hoff DD.Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development.Clin Cancer Res. 2002 Feb;8(2):314-46.
  • Carothers AM, Melstrom KA, Mueller JD, Weyant MJ, Bertagnolli MM.Progressive changes in adherens junction structure during intestinal adenoma formation in Apc mutant mice.J Biol Chem. 2001 Oct 19;276(42):39094-102.
  • Weyant MJ, Carothers AM, Mahmoud NN, Bradlow HL, Remotti H, Bilinski RT, Bertagnolli MM.Reciprocal expression of ERalpha and ERbeta is associated with estrogen-mediated modulation of intestinal tumorigenesis.Cancer Res. 2001 Mar 15;61(6):2547-51.
  • Weyant MJ, Carothers AM, Dannenberg AJ, Bertagnolli MM.(+)-Catechin inhibits intestinal tumor formation and suppresses focal adhesion kinase activation in the min/+ mouse.Cancer Res. 2001 Jan 1;61(1):118-25.
  • Bertagnolli MM.Cyclooxygenase-2 as a target for prevention of colorectal cancer.Curr Oncol Rep. 1999;1(2):173-8.
  • Mahmoud NN, Carothers AM, Grunberger D, Bilinski RT, Churchill MR, Martucci C, Newmark HL, Bertagnolli MM.Plant phenolics decrease intestinal tumors in an animal model of familial adenomatous polyposis.Carcinogenesis. 2000 May;21(5):921-7.
  • Weyant MJ, Carothers AM, Bertagnolli ME, Bertagnolli MM.Colon cancer chemopreventive drugs modulate integrin-mediated signaling pathways.Clin Cancer Res. 2000 Mar;6(3):949-56.
  • Bertagnolli MM.APC and intestinal carcinogenesis. Insights from animal models.Ann N Y Acad Sci. 1999;889:32-44.
  • Mahmoud NN, Dannenberg AJ, Bilinski RT, Mestre JR, Chadburn A, Churchill M, Martucci C, Bertagnolli MM.Administration of an unconjugated bile acid increases duodenal tumors in a murine model of familial adenomatous polyposis.Carcinogenesis. 1999 Feb;20(2):299-303.
  • Mahmoud NN, Bilinski RT, Churchill MR, Edelmann W, Kucherlapati R, Bertagnolli MM.Genotype-phenotype correlation in murine Apc mutation: differences in enterocyte migration and response to sulindac.Cancer Res. 1999 Jan 15;59(2):353-9.
  • Mahmoud NN, Dannenberg AJ, Mestre J, Bilinski RT, Churchill MR, Martucci C, Newmark H, Bertagnolli MM.Aspirin prevents tumors in a murine model of familial adenomatous polyposis.Surgery. 1998 Aug;124(2):225-31.
  • Mahmoud NN, Boolbol SK, Dannenberg AJ, Mestre JR, Bilinski RT, Martucci C, Newmark HL, Chadburn A, Bertagnolli MM.The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis.Carcinogenesis. 1998 Jan;19(1):87-91.
  • Mahmoud NN, Boolbol SK, Bilinski RT, Martucci C, Chadburn A, Bertagnolli MM.Apc gene mutation is associated with a dominant-negative effect upon intestinal cell migration.Cancer Res. 1997 Nov 15;57(22):5045-50.